Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cyclacel Pharmaceuticals (CYCC)
NASDAQ:CYCC
RESEARCH TOOLSreports
Holding CYCC?
Track your performance easily
CYCC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.95 - $11.34
Previous Close$1.02
Volume25.35K
Average Volume (3M)76.68K
Market Cap
$1.93M
Enterprise Value-$3.98M
Total Cash (Recent Filing)$6.00M
Total Debt (Recent Filing)$5.00K
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Nov 13, 2024EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-17.52
Shares Outstanding1,974,204
10 Day Avg. Volume23,588
30 Day Avg. Volume76,679
Standard Deviation0.26
R-Squared0.01
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)2.00
Price to Sales (P/S)25.79
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-49.77
Enterprise Value/Gross Profit-9.48
Enterprise Value/Ebitda0.20
Forecast
1Y Price Target
$11.00Price Target Upside1022.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Cyclacel Pharmaceuticals News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CYCC FAQ
What was Cyclacel Pharmaceuticals’s price range in the past 12 months?
Cyclacel Pharmaceuticals lowest stock price was $0.95 and its highest was $11.34 in the past 12 months.
What is Cyclacel Pharmaceuticals’s market cap?
Currently, no data Available
When is Cyclacel Pharmaceuticals’s upcoming earnings report date?
Cyclacel Pharmaceuticals’s upcoming earnings report date is Nov 13, 2024 which is in 53 days.
How were Cyclacel Pharmaceuticals’s earnings last quarter?
Cyclacel Pharmaceuticals released its earnings results on Aug 14, 2024. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$1.435 by $0.715.
Is Cyclacel Pharmaceuticals overvalued?
According to Wall Street analysts Cyclacel Pharmaceuticals’s price is currently Undervalued.
Does Cyclacel Pharmaceuticals pay dividends?
Cyclacel Pharmaceuticals does not currently pay dividends.
What is Cyclacel Pharmaceuticals’s EPS estimate?
Cyclacel Pharmaceuticals’s EPS estimate is -$0.56.
How many shares outstanding does Cyclacel Pharmaceuticals have?
Cyclacel Pharmaceuticals has 1,974,204 shares outstanding.
What happened to Cyclacel Pharmaceuticals’s price movement after its last earnings report?
Cyclacel Pharmaceuticals reported an EPS of -$0.72 in its last earnings report, beating expectations of -$1.435. Following the earnings report the stock price went down -8.966%.
Which hedge fund is a major shareholder of Cyclacel Pharmaceuticals?
Currently, no hedge funds are holding shares in CYCC
---
Cyclacel Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (1022.33% Upside)
$11.00 (1022.33% Upside)
Blogger Sentiment
Bullish
CYCC Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.77%
12-Months-Change
Fundamentals
Return on Equity
-329.40%
Trailing 12-Months
Asset Growth
-50.19%
Trailing 12-Months
Company Description
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
---
CYCC Earnings Call
Q2 2024
0:00 / 0:00
---
CYCC Stock 12 Month Forecast
Average Price Target
$11.00
▲(1022.33% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Aileron Therapeutics
―
CASI Pharmaceuticals
―
Kintara Therapeutics
―
Best Analysts Covering CYCC
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
-22.43%
assigned a buy rating last month
Copying Jonathan Aschoff's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -22.43% per trade.
---